|Bid||21.72 x 200|
|Ask||21.82 x 100|
|Day's Range||21.60 - 22.34|
|52 Week Range||14.72 - 25.79|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.25|
SOUTH SAN FRANCISCO, Calif., March 19, 2018-- Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced ...
Partnership aims to develop drugs for neurodegenerative diseases Denali will draw on Lonza’ s expertise in developing and manufacturing complex biologic molecules BASEL, Switzerland and SOUTH SAN FRANCISCO, ...
Takeda Pharmaceutical Company Limited and Denali Therapeutics today announced that they have entered into a strategic option and collaboration agreement to develop and commercialize up to three specified therapeutic product candidates for neurodegenerative diseases.
Here's one VC's snow-infused thoughts on Biotech’s 2018 Outlook with a few things to be both excited and worried about for the year and beyond.
A Morgan Stanley analyst predicts near-term upside for the shares of Denali Therapeutics Inc. (NASDAQ: DNLI ), thanks to its work in neuroscience and particularly its lead programs in Parkinson's and Alzheimer's. ...
Denali Therapeutics Inc. (NASDAQ: DNLI ), a biotech company focusing on therapies for neurodegenerative disorders, IPO-ed in Dec. 2017, offering 13.9 million shares at $18 each. The Analyst Goldman Sachs ...
Menlo Therapeutics Inc. filed Thursday to raise up to about $98 million in what could be the first IPO of the New Year from the Bay Area. South San Francisco-based Denali Therapeutics Inc. (DNLI) raised $229 million earlier this month and San Jose-based Restoration Robotics (HAIR) raised $25 million in mid-October. Menlo Therapeutics started out in 2011 under the name Tigercat Pharma Inc. and changed its name to Menlo Therapeutics in May 2016. It has raised about $110 million in funding, including a July round of $50 million this year that gave it a valuation of about $210 million, according to PitchBook Data.
Denali Therapeutics entered the markets with a bang on Friday. In its initial public offering, the company priced its almost 14 million shares within the expected range.